Consortium of MS Centers (CMSC) =MS neurologist bias against CCSVI (from CCSVI in MS by Joan Beal)
by Sief Hart on Friday, May 6, 2011 at 1:56am
Today's shocking revelation is that the Consortium of Multiple Sclerosis Centers (CMSC) was laundering money for kickbacks to neurologists by Merck Serono and that Executive Director June Halper was the head of this program.
Frank Timmons, Serono employee stated to Amato,
"We have a whole money-laundering thing going on with June Halper."
Here is the case Amato vs. Serono with details of the $500,000 total checks given to CMSC by Serono and funneled through to neurologists...
I believe it is imperative we ask what money the CMSC is taking in, and what they are doing with this funding.
This is the mission statement of the CMSC--
Our Mission: to be the preeminent professional organization for multiple sclerosis (MS) healthcare providers and researchers in North America, and a valued partner in the global MS community. Our core purpose is to maximize the ability of MS healthcare professionals to impact care of people who are affected by MS, thus improving their quality of life.
Are there are conflicts of interest between CMSC and CCSVI research, due to the coercion of pharmaceutical companies?
Here are some of the officers of CMSC:
Mark Freedman, MD--Director of Membership
Robert Lisak, MD--Director of Research
Timothy Vollmer, PhD. Director of CMSC NARCOMS
Micheal Yeung, MD-Co-Chair Education
http://www.mscare.org/cmsc/News/Committ ... jects.html
These very same doctors were the first to criticize CCSVI research, claiming it was a hoax.
Lisak and Freedman were very negative in their review in the Annals of Neurology http://www.ncbi.nlm.nih.gov/pubmed/20373339
Yeung was on the CIHR panel to reject CCSVI studies
Vollmer is the current head of the Rocky Mountain MS Center and wrote his thoughts on CCSVI here:
http://livingwell.mscenter.org/news/339 ... csvi-.html
One of the CMSC's largest programs is NARCOMS---
NARCOMS is a global registry for Multiple Sclerosis research, treatment, and patient education. The Registry is an active database of over 35,000 persons with Multiple Sclerosis. And the Director of the Statistical and Coordinating Center project is Dr. Gary Cutter at the University of Alabama.
NARCOMS is a project of the Consortium of Multiple Sclerosis Centers and is supported by grants and in-kind services from United Spinal Association, Paralyzed Veterans Association (PVA), and the National Multiple Sclerosis Society. Additional support has been provided byunrestricted grants from the following pharmaceutical companies: Berlex, Biogen, Serono, and Teva Neuroscience.
I keep seeing the same names and pharmaceutical connections. After today's revelation of improper funneling of pharma money through the CMSC, I believe the entire community of people with MS and their families need to get to the truth about this organization.
Serono worked out a deal with the Feds
1eye wrote:Serono worked out a deal with the Feds
How does that work, exactly? Who gave who $44 million? It sounds like Amato agreed to back off the jury trial if Serono gave him $44 million.
Wonder what the line item for that one is in the financial statement? It's still small change when you look at Rebif profits.
Maybe a few bucks came from some physicians who stood to be named? What does the U.S. get out of this deal?
ikulo wrote:In this case, the federal government and state governments that were defrauded would split the pot of ~$44m, and Amato would get a small percentage (probably a few million) from the federal share.
Tim received a hefty payment, and he is not allowed to speak about this case anymore.
Serono denies the allegations and doesn’t admit any liability, according to the settlement. Merck KGaA, based in Darmstadt, Germany, acquired Swiss drugmaker Serono SA in 2007 for $17.9 billion.
Under the agreement, the federal government will receive $34.6 million while various states will split $9.7 million.
1eye wrote: What's the big difference here?
• Mr. Hatch cast the only dissenting vote in the Senate in 2003 on an amendment that would reduce protections that the pharmaceutical companies used to block generic drugs from entering the market.
• The Center for Public Integrity (CPI), a nonprofit government watchdog organization, said that in 2006 Mr. Hatch took seven trips costing a total of $12,000 sponsored by Pfizer and GlaxoSmithKline, as well as two industry trade groups, the California Healthcare Institute and the Healthcare Leadership Council. At the time, he held $18,000 worth of stock in Pfizer and Novartis, the Swiss-based manufacturer of Ritalin, the drug that treats attention-deficit (hyperactivity) disorder.
• Mr. Hatch co-sponsored a Medicare bill while holding shares in Pfizer and Novartis, according to his 2003 financial disclosure forms. In statement at the time to CPI, Mr. Hatch defended the stock holdings, saying they represented a small percentage of his investment portfolio. He also characterized his travel as “legitimate activity under Senate rules,” adding that he “likes to have open communication with industry leaders.”
• After using a complimentary Gulfstream executive jet provided by drugmaker Schering-Plough Corp. for his long-shot presidential campaign in 2000, he drafted legislation extending the drug company’s patent on the drug Claritin.
Users browsing this forum: ALA